Center for Translational Nanomedicine - CTN
The Max-Planck-Institute for Polymer Research (MPIP) and the University Medicine of the Johannes Gutenberg-University Mainz join forces to create an interdisciplinary center to bring innovative drug delivery systems to the clinic. This bridges the gap between medical need and excellent basic science. Nanocarrier research is focused on altering the body distribution of drugs such that lower doses can be used. This results in lower side effects and/or higher effectiveness. Classical pharmaceutical approaches as well as novel immune modulating agents to treat cancer and (auto)immune diseases like rheumatitis are the focus of the CTN.
- identify medical needs from applications in clinical use
- translate the medical need into a scientific question
- understand opportunities and obstacles of nanocarriers in the complex biological surrounding of blood plasma and in whole organisms
- to develop a process which uses pharmaceutical grade excipients that can be transformed into a good-manufacturing-production (GMP) process
- develop assays for testing of nanocarriers during production and for a batch-to-batch release
- perform the crucial in vivo studies for effectiveness and toxicology
- transform this towards a process performed in a small-medium enterprise (SME)
How to become a member of CTN?
CTN is in the process of becoming an interdisciplinary working group (“Interdisziplinärer Arbeitskreis – IAK”) according the rules of the JGU. According to these we will form the consortium of the CTN. If you want to express your interest of becoming a member of CTN please contact us by sending your statement of interest to email@example.com
- Prof. Dr. Volker Mailänder, Dermatology Clinic, University Medicine of the Johannes Gutenberg University (JGU), Mainz
- Prof. Dr. Katharina Landfester, Physical Chemistry of Polymers, Max Planck Institute for Polymer Research), Mainz
- Prof. Dr. Stephan Grabbe, Dermatology Clinic, University Medicine of the Johannes Gutenberg University (JGU), Mainz